Lipids and lipoproteins in calcific aortic valve disease.
Olcay Aksoy, Yin Tintut, Linda L Demer
https://pubmed.ncbi.nlm.nih.gov/42592935/Actively Recruiting
Led by Kardigan, Inc. · Updated on 2026-07-06
1276
Participants Needed
74
Research Sites
108 weeks
Total Duration
Researchers are evaluating whether ataciguat can slow the progression of moderate calcific aortic valve stenosis CAVS in adults aged 50 and older. This study is conducted in two parts Part A focuses on whether ataciguat reduces calcium buildup in the aortic valve over 24 weeks, while Part B examines if the drug slows narrowing of the valve area and improves peak oxygen consumption over 48 weeks. Safety, tolerability, and how the body processes ataciguat are also assessed. Participants receive either ataciguat or a placebo daily for up to 156 weeks. Part A enrolls about 132 participants, and Part B will begin after Part A completes, enrolling around 1144 participants. Part B includes additional evaluation of heart function and ability to exercise. The study uses a randomized, double-blind design, meaning neither participants nor researchers know who receives the drug or placebo. During the study, participants undergo imaging tests like CT scans and echocardiograms to measure valve calcium and valve area. Cardiopulmonary exercise testing CPET is used to assess peak oxygen consumption. Researchers also monitor heart function, symptoms, and quality of life using questionnaires. Assessments occur mainly at baseline, Week 24, and Week 48, with long-term follow-up to 156 weeks for safety and efficacy. The studys total duration extends to 2030.
CONDITIONS
Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
K
Kardigan Clinical Trial Information Team
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Kardigan, Inc.
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Ataciguat | Placebo |
|---|---|---|
| What it is | Ataciguat is an investigational oral drug given daily, studied for its ability to slow progression of moderate calcific aortic valve stenosis (CAVS). | Placebo is an inactive oral pill, administered daily and matched in appearance and schedule to ataciguat. |
| Role in trial | Represents the investigational drug arm, assigned to receive ataciguat. | Serves as the placebo comparator arm, assigned to receive matched inactive pill. |
| Primary use / rationale | To evaluate whether ataciguat can slow the progression of moderate CAVS, as measured by changes in aortic valve calcification, valve area, and exercise capacity. | To serve as a blinded comparator for assessing progression of CAVS without active drug intervention. |
| How it is given or performed | Oral dosing, once daily for up to 156 weeks. | Oral dosing, once daily for up to 156 weeks, matching the investigational arm. |
| Evidence status (beyond this trial) | Effectiveness and safety in slowing CAVS progression are not yet established. There are no published results demonstrating benefits or risks for ataciguat in moderate CAVS as of now. | Placebo does not provide therapeutic benefit in CAVS and is used as a comparator for controlled assessment. |
| Important limitations / clinical context | Long-term impact on delaying the need for aortic valve intervention, mortality, or quality of life remains unproven. Ataciguat does not address the underlying causes of valve degeneration. Management of moderate CAVS is currently focused on monitoring and risk factor management; no medical therapy has been clearly shown to halt progression. | Placebo does not alter disease course. Standard management for moderate CAVS focuses on regular follow-up, symptom assessment, and control of cardiovascular risk factors; there is no proven medical treatment to stop valve progression to date. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 156 weeks
Participants receive daily doses of either ataciguat or placebo for up to 156 weeks to study effects on aortic valve stenosis.
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Olcay Aksoy, Yin Tintut, Linda L Demer
https://pubmed.ncbi.nlm.nih.gov/42592935/Kardigan, Inc.
Lead Sponsor